Following a U.S. National Cohort of Vulnerable Men to Improve HIV Prevention and Care
跟踪美国国家弱势男性群体改善艾滋病毒预防和护理
基本信息
- 批准号:10265712
- 负责人:
- 金额:$ 78.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS preventionAddressAgeBehaviorBehavioralBiologicalBisexualCaringCenters for Disease Control and Prevention (U.S.)Cohort StudiesColorConsentContinuity of Patient CareDataDiagnosisEligibility DeterminationEnrollmentEpidemiologyEventGaysGeographyGuidelinesHIVHIV SeronegativityHIV SeropositivityHawthorne EffectHomeHuman immunodeficiency virus testIncentivesIncidenceIndividualInfectionInternetInterventionLatinoLogisticsMediatingMethodsModalityMonitorMovementNewly DiagnosedParticipantPersonsPhasePopulationPreventionPrevention ResearchResearchResearch DesignResearch PersonnelRiskSamplingSelf AdministrationStructureSurveysTechnologyTelephone InterviewsTest ResultTestingTime trendagedbasecohortcomputerizedcontextual factorscostdesigndigitalfollow-uphigh riskhigh risk menhigh risk populationimprovedinfection riskinnovative technologiesmeetingsmembermenmen who have sex with menminimally invasiveonline deliveryonline interventionpre-exposure prophylaxisprospectivepsychosocialracial and ethnic disparitiesracial disparityrecruitresearch studysample collectionscreeningseroconversiontransmission processuptakeurban setting
项目摘要
Project Summary
RFA-AI-16-031 (LITE) is designed to address critical needs in HIV prevention research by using innovative
technology to enroll and follow large-scale epidemiological cohorts of those at highest risk of infection. The
proposed project will utilize established Internet-based strategies, previously used successfully by the research
team, to enroll a sample of 5,000 high-risk HIV-negative gay, bisexual, and other men who have sex with men
(GBM) ages 16 to 49—the population representing the highest percentage of new infections annually—and
follow them prospectively for four years. The design features of our proposal were chosen specifically to: (a)
identify individual-, network-, and contextual-level predictors and correlates of HIV seroconversion, (b) identify
missed HIV prevention opportunities among those seroconverting during the course of the study, and, thus (c)
inform interventions to further reduce acquisition and transmission.
We define “high-risk” as meeting CDC guidelines for PrEP treatment, but not taking PrEP. Participants will
complete annual self-administered at-home rapid HIV testing (results submitted via digital photo of the test
paddle) as well as brief (~20 min) at-home computerized surveys. In addition to being referred for treatment,
study participants who seroconvert will complete a semi-structured telephone interview to identify missed HIV
prevention opportunities and the contextual factors involved. We will monitor newly diagnosed participants'
movement through the HIV care continuum. Based on current incidence rates, we anticipate accumulating
~252 infections during the study; however, because we are targeting high-risk men, this number could be
higher.
Aim 1 (UG3 Phase): Establish a cohort of 5,000 high-risk HIV-negative GBM who are not on PrEP, all of
whom complete baseline online surveys and at-home self-administered HIV testing, as well as consent for
longitudinal follow-up. Determine PrEP uptake and HIV incidence 12 months after study enrollment.
Supplemental Aims: Using the cross sectional data from GBM deemed ineligible during screening for study
eligibility: Sup. Aim 1a—Estimate the uptake of PrEP; and Sup. Aim 1b—Characterize missed HIV
prevention opportunities (e.g., reasons for no prior PrEP use) among recent HIV seroconverters.
Aim 2 (UH3 Phase): Follow the cohort for four years to characterize (2a) individual/network/contextual-level
determinants of PrEP uptake/discontinuation; (2b) new HIV seroconversions and missed HIV prevention
opportunities, including individual/network/contextual-level determinants; (2c) racial/ethnic disparities in
HIV incidence and their trends over time; and (2d) the influence of PrEP uptake on racial/ethnic disparities.
项目摘要
RFA-AI-16-031(LITE)旨在通过使用创新的方法来满足艾滋病毒预防研究的关键需求。
在这方面,我们需要一种新的技术,以登记和跟踪感染风险最高者的大规模流行病学队列。的
拟议的项目将利用既定的基于互联网的战略,以前成功地用于研究
研究小组招募了5,000名高风险的艾滋病毒阴性同性恋、双性恋和其他男男性行为者的样本
(GBM)年龄在16至49岁之间的人-这一人群每年新感染的比例最高,
跟踪他们四年。我们建议的设计特点是专门为:(a)
鉴定HIV血清转化个体、网络和背景水平的预测因子和相关因子,(B)鉴定
在研究过程中,在血清转化者中错过了艾滋病毒预防机会,因此(c)
采取知情干预措施,进一步减少感染和传播。
我们将“高风险”定义为符合CDC的PrEP治疗指南,但不服用PrEP。
完成每年一次的自我管理的家庭快速艾滋病毒检测(通过检测的数码照片提交结果
桨)以及简短的(约20分钟)在家里的计算机化调查。除了接受治疗外,
血清转换的研究参与者将完成半结构化电话访谈,以确定遗漏的HIV
预防机会和所涉及的背景因素。我们将监测新诊断的参与者
通过艾滋病毒护理连续体的运动。根据目前的发病率,我们预计
研究期间约有252例感染;然而,由于我们针对的是高危男性,因此这一数字可能是
高
目标1(UG 3阶段):建立一个由5,000名未接受PrEP的高危HIV阴性GBM组成的队列,所有患者均为
完成基线在线调查和在家自我管理的艾滋病毒检测,以及同意
纵向跟踪。确定研究入组后12个月的PrEP摄取和HIV发病率。
补充目的:使用筛选期间被视为不合格的GBM的横断面数据
资格:UP。目标1a-估计PrEP的摄取;和Sup.目标1b-鉴别漏诊的艾滋病毒
预防机会(例如,没有事先使用PrEP的原因)。
目标2(UH 3阶段):跟踪队列4年,以表征(2a)个人/网络/背景水平
PrEP摄取/中止的决定因素;(2b)新的HIV血清转换和错过的HIV预防
机会,包括个人/网络/背景一级的决定因素;(2c)
艾滋病毒发病率及其随时间的趋势;(2d)PrEP摄取对种族/民族差异的影响。
项目成果
期刊论文数量(38)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Awareness and Acceptability of Undetectable = Untransmittable Among a U.S. National Sample of HIV-Negative Sexual and Gender Minorities.
- DOI:10.1007/s10461-020-02990-3
- 发表时间:2021-03
- 期刊:
- 影响因子:4.4
- 作者:Carneiro PB;Westmoreland DA;Patel VV;Grov C
- 通讯作者:Grov C
Engagement in Care Among Newly Diagnosed HIV-Positive Gay, Bisexual, and Other Men Who Have Sex With Men in the United States: Results From the Together 5,000 Study.
- DOI:10.1521/aeap.2022.34.5.349
- 发表时间:2022-10
- 期刊:
- 影响因子:1.8
- 作者:Rios, Javier Lopez;Lentz, Cody;Balan, Ivan C.;Grosskopf, Nicholas;D'Angelo, Alexa;Stief, Matthew;Grov, Christian
- 通讯作者:Grov, Christian
Sociocultural influences on attitudes towards pre-exposure prophylaxis (PrEP), history of PrEP use, and future PrEP use in HIV-vulnerable cisgender men who have sex with men across the U.S.
- DOI:10.1891/lgbtq-2020-0005
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Westmoreland DA;Patel VV;D'Angelo AB;Nash D;Grov C
- 通讯作者:Grov C
"I stretch them out as long as possible:" U.S. women's experiences of menstrual product insecurity during the COVID-19 pandemic.
- DOI:10.1186/s12905-023-02333-z
- 发表时间:2023-04-15
- 期刊:
- 影响因子:2.5
- 作者:Schmitt, Margaret L.;Dimond, Katie;Maroko, Andrew R.;Phillips-Howard, Penelope A.;Gruer, Caitlin;Berry, Amanda;Nash, Denis;Kochhar, Shivani;Sommer, Marni
- 通讯作者:Sommer, Marni
Changes in Cost and Insurance Challenges to Cover PrEP Between 2019 and 2021.
2019 年至 2021 年间 PrEP 的成本和保险挑战的变化。
- DOI:10.1097/qai.0000000000003180
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:D'Angelo,AlexaB;Mirzayi,Chloe;Carneiro,PedroB;Grov,Christian
- 通讯作者:Grov,Christian
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christian Grov其他文献
Christian Grov的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christian Grov', 18)}}的其他基金
Following a U.S. National Cohort of Vulnerable Men to Improve HIV Prevention and Care
跟踪美国国家弱势男性群体改善艾滋病毒预防和护理
- 批准号:
9393530 - 财政年份:2017
- 资助金额:
$ 78.77万 - 项目类别:
Following a U.S. National Cohort of Vulnerable Men to Improve HIV Prevention and Care
跟踪美国国家弱势男性群体改善艾滋病毒预防和护理
- 批准号:
10204965 - 财政年份:2017
- 资助金额:
$ 78.77万 - 项目类别:
Club drug use and PrEP adherence in vulnerable men
弱势男性俱乐部吸毒和 PrEP 依从性
- 批准号:
9110935 - 财政年份:2015
- 资助金额:
$ 78.77万 - 项目类别:
Club drug use and PrEP adherence in vulnerable men
弱势男性俱乐部吸毒和 PrEP 依从性
- 批准号:
9419433 - 财政年份:2015
- 资助金额:
$ 78.77万 - 项目类别:
Syndemics and resilience for HIV transmission in a national sample of vulnerable
全国弱势群体样本中的流行病和艾滋病毒传播的恢复力
- 批准号:
8605791 - 财政年份:2013
- 资助金额:
$ 78.77万 - 项目类别:
Syndemics and resilience for HIV transmission in a national sample of vulnerable
全国弱势群体样本中的流行病和艾滋病毒传播的恢复力
- 批准号:
9246514 - 财政年份:2013
- 资助金额:
$ 78.77万 - 项目类别:
Syndemics and resilience for HIV transmission in a national sample of vulnerable
全国弱势群体样本中的流行病和艾滋病毒传播的恢复力
- 批准号:
8819527 - 财政年份:2013
- 资助金额:
$ 78.77万 - 项目类别:
Syndemics and resilience for HIV transmission in a national sample of vulnerable
全国弱势群体样本中的流行病和艾滋病毒传播的恢复力
- 批准号:
8884903 - 财政年份:2013
- 资助金额:
$ 78.77万 - 项目类别:
Syndemics and resilience for HIV transmission in a national sample of vulnerable
全国弱势群体样本中的流行病和艾滋病毒传播的恢复力
- 批准号:
8853494 - 财政年份:2013
- 资助金额:
$ 78.77万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 78.77万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 78.77万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 78.77万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 78.77万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 78.77万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 78.77万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 78.77万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 78.77万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 78.77万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 78.77万 - 项目类别:
Research Grant